Highlights and Quick Summary
- Annual Inventory Turnover for 2021 was 0.0 (a NaN% decrease from previous year)
- Annual Inventory Turnover for 2020 was 0.0 (a NaN% decrease from previous year)
- Annual Inventory Turnover for 2019 was 0.0 (a NaN% decrease from previous year)
- Twelve month Inventory Turnover ending December 31, 2021 was 0.0 (a NaN% decrease compared to previous quarter)
- Twelve month trailing Inventory Turnover decreased by NaN% year-over-year
Trailing Inventory Turnover for the last four month:
| 31 Dec '21 | 30 Sep '21 | 30 Jun '21 | 31 Mar '21 |
|---|---|---|---|
| 0.0 | 0.0 | 0.0 | 0.0 |
Visit stockrow.com/TERN
for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow
statement with 10 years of data, and state-of-the-art screener.
Historical Inventory Turnover of Terns Pharmaceuticals, Inc.
Most recent Inventory Turnoverof TERN including historical data for past 10 years.Interactive Chart of Inventory Turnover of Terns Pharmaceuticals, Inc.
Terns Pharmaceuticals, Inc. Inventory Turnover for the past 10 Years (both Annual and Quarterly)
| Year | Q1 | Q2 | Q3 | Q4 | Fiscal Year |
|---|---|---|---|---|---|
| 2021 | – | – | – | – | 0.0 |
| 2020 | – | – | – | – | 0.0 |
| 2019 | – | – | – | – | 0.0 |
| 2018 | – | – | – | – | 0.0 |
Business Profile of Terns Pharmaceuticals, Inc.
Sector: Healthcare
Industry: Biotechnology
Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis (NASH) and obesity. The company develops TERN-101, a liver-distributed and non-bile acid farnesoid X receptor agonist, which is in Phase IIa clinical trial for the treatment of NASH; and TERN-201, a vascular adhesion protein-1 inhibitor that is in Phase Ib clinical trial for the treatment of NASH. It also develops TERN-501, a thyroid hormone receptor beta agonist with enhanced liver distribution and metabolic stability that is in Phase I clinical trial for the treatment of NASH; and TERN-601, a small-molecule Glucagon-Like Peptide-1 receptor agonist program that is intended to orally be administered for NASH and metabolic diseases, such as obesity. The company was incorporated in 2016 and is headquartered in Foster City, California.